TGEN Director Granted 25,000 Options at $8.35 鈥� Form 4 Insight

Q: What did Tecogen (TGEN) disclose in the July 2025 Form 4?

Director Susan B. Hirsch was granted 25,000 stock options at an exercise price of $8.35 on 07/24/2025.

Q: How many Tecogen options does Susan B. Hirsch own after the transaction?

She holds 150,000 derivative securities (stock options) directly.

Q: Do the Form 4 filings indicate any Tecogen stock sales by the director?

No. The filing reports only an option grant ; no shares were sold or purchased on the open market.

Q: What is the expiration date of the Tecogen director鈥檚 new options?

The options expire on 07/24/2035 .

[Form 4] Tecogen Inc. Insider Trading Activity

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Form 4 鈥� Tecogen Inc. (TGEN)

Reporting person: Susan B. Hirsch, Director.
Transaction date: 07/24/2025.
Instrument: Stock Option (right to buy) covering 25,000 common shares at an exercise price of $8.35.
Vesting: 25 % per year; first exercisable 07/24/2026; expiration 07/24/2035.
Post-transaction holdings: Hirsch now directly holds 150,000 derivative securities (options).

No non-derivative (common stock) transactions were reported. The filing reflects a routine option grant to a board member and does not disclose cash compensation, sale activity, or changes in direct share ownership.

Positive

Director receives additional long-dated options, signaling ongoing commitment and potential future alignment with shareholder value.

Negative

None.

Insights

TL;DR: Routine option grant; limited impact on valuation.

The filing records a standard director option award of 25 k shares at $8.35. It increases Hirsch鈥檚 derivative exposure to 150 k options, reinforcing alignment with shareholder interests but does not involve open-market buying or selling of common stock. No immediate dilution occurs because options are long-dated and vest over four years. Given Tecogen鈥檚 small-cap profile, the size is modest and unlikely to alter float, earnings, or insider-sentiment metrics materially. I view the disclosure as administratively neutral.

07/28/2025 - 11:02 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Hirsch Susan B

(Last)

(First)

(Middle)

280 OLD SOMERSET ROAD

(Street)

WATCHUNG

07069

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
TECOGEN INC. [ TGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$8.35	07/24/2025		A		25,000		07/24/2026⁽¹⁾	07/24/2035	Common Stock	25,000	$8.35	150,000	D

Explanation of Responses:

1. Vests 25% per year

Remarks:

	/s/ Susan B. Hirsch	07/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What did Tecogen (TGEN) disclose in the July 2025 Form 4?

Director Susan B. Hirsch was granted 25,000 stock options at an exercise price of $8.35 on 07/24/2025.

How many Tecogen options does Susan B. Hirsch own after the transaction?

She holds 150,000 derivative securities (stock options) directly.

When can the newly granted Tecogen options be exercised?

They begin vesting 25 % per year and are first exercisable on 07/24/2026.

Do the Form 4 filings indicate any Tecogen stock sales by the director?

No. The filing reports only an option grant; no shares were sold or purchased on the open market.

What is the expiration date of the Tecogen director鈥檚 new options?

The options expire on 07/24/2035.

AG真人官方

[Form 4] Tecogen Inc. Insider Trading Activity

Insights

FAQ

What did Tecogen (TGEN) disclose in the July 2025 Form 4?

How many Tecogen options does Susan B. Hirsch own after the transaction?

When can the newly granted Tecogen options be exercised?

Do the Form 4 filings indicate any Tecogen stock sales by the director?

What is the expiration date of the Tecogen director鈥檚 new options?

NYSE:TGEN

TGEN Rankings

TGEN Latest News

TGEN Latest SEC Filings

TGEN Stock Data

AG真人官方

Trending News

[Form 4] Tecogen Inc. Insider Trading Activity

Insights

Securities Analyst neutral

FAQ

What did Tecogen (TGEN) disclose in the July 2025 Form 4?

How many Tecogen options does Susan B. Hirsch own after the transaction?

When can the newly granted Tecogen options be exercised?

Do the Form 4 filings indicate any Tecogen stock sales by the director?

What is the expiration date of the Tecogen director鈥檚 new options?

NYSE:TGEN

TGEN Rankings

TGEN Latest News

TGEN Latest SEC Filings

TGEN Stock Data